These findings elucidate the therapeutic mechanisms of CD40 targeting and modification of the TME in pancreatic cancer, aiming to enhance the effectiveness of immunotherapies against cold tumors like PDAC. The gene discussed is CD40; the disease is familial pancreatic carcinoma.